ASynPEP-DB: a database of biogenic peptides for inhibiting α-synuclein aggregation.

ABSTRACT: Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, yet effective treatments able to stop or delay disease progression remain elusive. The aggregation of a presynaptic protein, α-synuclein (aSyn), is the primary neurological hallmark of PD and, thus, a promising target for therapeutic intervention. However, the lack of consensus on the molecular properties required to specifically bind the toxic species formed during aSyn aggregation has hindered the development of therapeutic molecules. Recently, we defined and experimentally validated a peptide architecture that demonstrated high affinity and selectivity in binding to aSyn toxic oligomers and fibrils, effectively preventing aSyn pathogenic aggregation. Human peptides with such properties may have neuroprotec

SUBMITTER: Pintado-Grima C 

PROVIDER: S-EPMC10681447 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature